	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	31.78	30.17	32.77	33.59	42.83	46.55	82.04	131.38
Cost of Operating Revenue	29.28	26.69	29.19	26.17	35.08	39.30	67.10	116.06
Gross Profit	2.49	3.48	3.59	7.42	7.75	7.25	14.94	15.33
Gross Margin	7.8	11.5	10.9	22.1	18.1	15.6	18.2	11.7
Total Operating Expenses	30.61	28.55	30.89	28.60	39.33	42.45	74.84	120.75
Operating Profit	1.17	1.63	1.89	4.99	3.50	4.10	7.21	10.64
Operating Margin	3.7	5.4	5.8	14.9	8.2	8.8	8.8	8.1
Financing Income/(Expense) - Net	-0.74	-1.14	-1.15	-2.08	-1.42	-0.83	-1.08	-2.11
Profit before Taxes	0.42	0.50	0.75	3.80	3.72	3.80	6.14	8.60
Income Taxes	-0.12	-0.14	-0.20	0.99	0.91	0.49	1.98	2.20
Profit after Tax	0.54	0.63	0.95	2.81	2.81	3.31	4.16	6.40
PAT Margin	1.7	2.1	2.9	8.4	6.6	7.1	5.1	4.9
EPS - Basic - ex Extraordinary Items	0.09	0.10	0.16	1.47	0.92	0.96	1.20	1.94
EPS - Diluted - ex Extraordinary Items	0.09	0.10	0.16	1.47	0.92	0.96	1.20	1.94
EBIT	1.17	1.63	1.89	4.99	3.50	4.10	7.21	10.64
EBITDA	1.32	1.86	2.16	5.36	3.93	4.54	8.20	11.71
EBITDA Margin	4.2	6.2	6.6	16.0	9.2	9.8	10.0	8.9

Balance Sheet

Abridged

Understanding Balance Sheet

JFL Life Sciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	PR	PR	PR	AR	AR	AR	AR	AR
Total Current Assets	13.60	18.37	20.46	39.30	44.01	43.60	59.50	91.50
Long-Term Investments	-	-	-	-	0.33	0.15	0.17	0.21
Property Plant & Equipment - Net	2.51	5.05	6.50	7.13	6.80	12.47	12.24	14.54
Total Non-Current Assets	2.55	5.96	8.55	8.96	7.51	13.11	12.41	14.75
Total Assets	16.15	24.33	29.01	48.26	51.52	56.71	71.91	106.25
Total Current Liabilities	8.14	17.50	13.76	28.38	18.16	20.63	31.62	52.99
Long Term Debt	2.90	1.31	8.18	8.41	0.81	0.40	0.38	6.88
Total Non-Current Liabilities	3.00	1.45	8.37	8.59	1.09	0.51	0.84	7.39
Total Liabilities	11.13	18.95	22.13	36.97	19.25	21.13	32.46	60.38
Total Shareholders' Equity	5.01	5.38	6.87	11.29	32.27	35.58	39.46	45.87
Total Equity	5.01	5.38	6.87	11.29	32.27	35.58	39.46	45.87
Total Liabilities & Equity	16.15	24.33	29.01	48.26	51.52	56.71	71.91	106.25

Cash Flow

Abridged

Understanding Cash Flow Statement

JFL Life Sciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	C 2024 Mar 31	2025 Mar 31	2026 Mar 31
	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	C 2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	0.59	0.66	0.95	4.39	3.15	4.17	6.10	9.69
Working Capital - Increase/(Decrease)	-4.21	1.47	-7.93	-4.05	-13.63	3.40	-10.71	-16.06
Net CF from Operating Activities	-3.63	2.13	-6.98	0.34	-10.48	7.57	-4.60	-6.36
Capital Expenditures - Net	0.61	2.78	1.72	1.69	-0.24	6.11	0.40	3.38
Net CF from Investing Activities	-0.61	-2.78	-1.72	-0.81	0.86	-6.11	-0.02	-3.95
Dividends Paid - Cash - Total	-	-	-	-	-	-	0.28	-
Stock - Issuance/(Retirement) - Net	0.70	-	0.96	1.56	18.17	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	3.54	0.92	7.49	-0.94	-8.67	-1.49	4.90	11.14
Net Cash Flow from Financing Activities	4.24	0.92	8.45	0.62	9.49	-1.49	4.62	11.14
Free Cash Flow to Equity	-0.70	0.27	-1.22	-2.29	-18.91	-0.03	-0.10	1.40
Free Operating CF net dividend	-4.24	-0.65	-8.71	-1.35	-10.48	1.46	-5.28	-9.74
Free Operating CF	-4.24	-0.65	-8.71	-1.35	-10.48	1.46	-5.00	-9.74

Business Segment Analysis

JFL Life Sciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for JFL Life Sciences Ltd.

Regional Segment Analysis

JFL Life Sciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for JFL Life Sciences Ltd.

Historical Segment Analysis

Track how JFL Life Sciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for JFL Life Sciences Ltd.

Frequently Asked Questions

What is the revenue of JFL Life Sciences Ltd.?

The latest trailing twelve month revenue of JFL Life Sciences Ltd. is ₹ 131.38 Cr, reflecting a 1-year growth of 60.14% and a 3-year CAGR of 45.30%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of JFL Life Sciences Ltd.?

The latest trailing twelve month net profit (PAT) of JFL Life Sciences Ltd. is ₹ 6.40 Cr, with a 3-year earnings CAGR of 28.16%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of JFL Life Sciences Ltd.?

The trailing twelve month EBITDA of JFL Life Sciences Ltd. is approximately ₹ 10.64 Cr (based on an operating margin of 8.10%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of JFL Life Sciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of JFL Life Sciences Ltd. is 1.94. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of JFL Life Sciences Ltd.?

The debt-to-equity ratio of JFL Life Sciences Ltd. stands at 0.47. The interest coverage ratio is 5.05x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of JFL Life Sciences Ltd.?

The estimated book value per share of JFL Life Sciences Ltd. is 7.11 (derived from a P/B ratio of 1.57 and market price of ₹ 11.15), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of JFL Life Sciences Ltd.?

The trailing twelve month operating cash flow of JFL Life Sciences Ltd. is ₹ -6.36 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does JFL Life Sciences Ltd. report consolidated or standalone financials?

JFL Life Sciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.